On Feb 16, we issued an updated research report on Illumina, Inc. ILMN. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Illumina's (ILMN-5.63%) first-quarter results were full of exclamation points -- at least from an investor's perspective. Revenue jumped nearly 31% year over year. Adjusted earnings per share more ...

The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Examples of both strength and sluggishness are likely in the gene-sequencing pioneer's upcoming financial update. The company announces its full-year 2018 and fourth-quarter financial results after ...

Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above ...

The "Microarray Analysis Market by Product & Service (Consumables, Instrument, Software, Services), Type, Application (Research), End User (Diagnostic Laboratories, Pharmaceutical & Biotechnology ...

For most researchers DNA microarrays are synonymous with high-throughput gene expression analysis. But they also are invaluable genotyping tools. Now that the International HapMap Project (see article ...

Canaccord Genuity analyst Kyle Mikson CFA has maintained their neutral stance on ILMN stock, giving a Hold rating today. Geoff Meacham has given his Hold rating due to a combination of factors ...

Illumina's (NASDAQ: ILMN) first-quarter results were full of exclamation points -- at least from an investor's perspective. Revenue jumped nearly 31% year over year. Adjusted earnings per share more ...